Figures
- FIGURE 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart illustrating study selection process.
- FIGURE 2
Number of included studies by publication year.
- FIGURE 3
Forest plots showing pooled means and subgroup analysis for St George's Respiratory Questionnaire (SGRQ) and Short Form 36 (SF36). QOL: quality of life.
- FIGURE 4
Forest plots showing pooled means and sub-group analysis for EuroQoL (EQ5D) and King’s Brief Interstitial Lung Disease questionnaire (KBILD). QOL: quality of life.
- FIGURE 5
Summary plots for sensitivity analyses and funnel plot for assessment of publication bias. QOL: quality of life; EQ5D: EuroQoL; SGRQ: St George's Respiratory Questionnaire; SF36: Short Form-36; KBILD: King's Brief Interstitial Lung Disease questionnaire.
Tables
- TABLE 1
Summary of all studies included in the review
Study [ref.] Country Year Study type Clinical diagnosis standards (CDS) CDS year Measurement instrument Population characteristics Sample size Male sex Mean age Mean FVC% De Vries et al. [77] Netherlands 2000 Cohort study NR NR SGRQ
WHOQOL10 40 61.1 79.6 Martinez et al. [43] Brazil 2000 Cross-sectional study NR NR SF36 34 59 52.3 62.4 Clark et al. [78] UK 2001 Prospective observational study ATS/ERS 2000 SF36 50 66 67.7 80.9 De Vries et al. [31] Netherlands 2001 Cross-sectional study ATS/ERS 2000 WHOQOL 41 37 63.5 NR Baddini et al. [38] Brazil 2002 Cohort study ATS/ERS 2000 SF36 30 60 58.6 61.9 Jastrzebski et al. [41] Poland 2005 Cross-sectional study ATS/ERS 2000 SF36 16 69 48.3 44.0 Nishiyama et al. [79] Japan 2005 Prospective observational study ATS/ERS 2000 SGRQ 41 85 64.0 76.6 Tomioka et al. [80] Japan 2005 RCT ATS/ERS 2000 SF36 22 NR 70.0 72.5 Tzanakis et al. [81] Sweden 2005 Cross-sectional study ATS/ERS 2000 SGRQ 25 80 66.0 68.8 Antoniou et al. [82] Greece 2006 RCT ATS/ERS 2000 SGRQ 50 84 66.9 71.4 Tomioka et al. [83] Japan 2007 Cross-sectional and longitudinal study ATS/ERS 2000 SF36 46 70 69.9 71.0 Zimmermann et al. [84] Brazil 2007 Cross-sectional study ATS/ERS 2000 SGRQ
SF3620 NR 61.5 70.4 Feltrim et al. [39] Brazil 2008 Cross-sectional cohort study NR NR SGRQ 7 57 54.1 NR King et al. [85] Multi-country 2008 RCT (BUILD-1) ATS/ERS 2002 SGRQ
SF36154 73 65.2 67.8 Krishnan et al. [86] USA 2008 Cross-sectional study ATS/ERS 2000 SF36 39 54 67.7 68.9 Nishiyama et al. [87] Japan 2008 RCT ATS/ERS 2000 SGRQ 28 75 66.2 67.5 Peng et al. [88] China 2008 Cross-sectional and longitudinal study ATS/ERS 2000 SGRQ 68 64.0 66.0 Raghu et al. [89] USA 2008 RCT ATS/ERS 2000 SGRQ
SF3687 68 65.2 63.9 Han et al. [90] USA 2009 Cross-sectional study ATS/ERS 2000 SGRQ
SF12221 67 63.0 62.9 IPF Clinical Research Network et al. [91] USA 2010 RCT (STEP-IPF) ATS/ERS 2000 SGRQ
EQ5D
SF36180 83 69.0 56.8 Jastrzebski et al. [42] Poland 2010 Cross-sectional study NR NR SGRQ
SF3630 80 52.2 41.2 Key et al. [92] UK 2010 Cross-sectional study ATS/ERS 2002 LCQ NR 74 70.8 78.5 Lindell et al. [93] USA 2010 Mixed method intervention study ATS/ERS 2000 SF36 21 76 66.2 NR Lutogniewska et al. [51] Poland 2010 NR NR NR SGRQ
SF3630 NR NR NR Ozalevli et al. [94] Turkey 2010 Prospective observational study ATS/ERS 2000 SF36 15 67 62.8 71.6 Raghu et al. [95] Multi-country 2010 RCT (BUILD-1) ATS/ERS 2000 SGRQ 154 73 65.2 67.8 Swigris et al. [74] USA 2010 Cohort study ATS/ERS 2000 ATAQ-IPF 95 82 69.3 66.0 Swigris et al. [76] USA 2010 RCT (BUILD-1) ATS/ERS 2000 SGRQ
SF36100 73 65.1 66.97 du Bois et al. [96] Multi-country 2011 RCT ATS/ERS 2000 SGRQ 822 71 66.0 72.5 Elfferich et al. [49] Netherlands 2011 Cross-sectional study other NR WHOQOL 49 63 63.1 82.9 Jones et al. [97] UK 2011 Case control study ATS/ERS 2002 LCQ NR 63 72.0 80.4 King et al. [98] Multi-country 2011 RCT (BUILD-3) ATS/ERS 2000 SF36
EQ5D581 70 63.8 74.5 Kozu et al. [99] Japan 2011 Prospective non-randomised open trial ATS/ERS 2000 SF36 45 82 67.5 68.6 Kozu et al. [100] Japan 2011 Prospective non-randomised, and uncontrolled study ATS/ERS 2000 SF36 65 71 67.5 65.3 Mishra et al. [101] India 2011 RCT ATS/ERS 2002 SGRQ NR 100 70.7 61.4 Rammaert et al. [102] France 2011 Prospective observational study ATS/ERS 2000 SGRQ
SF36NR 62 67.1 67.0 Swigris et al. [103] USA 2011 Prospective observational study ATS/ERS 2000 SF36 21 86 71.5 73.0 Verma et al. [45] Canada 2011 Cross-sectional study ATS/ERS 2000 SGRQ
SF36137 66 59.4 61.7 Horton et al. [50] USA 2012 RCT other NR SGRQ
CQLQ23 78 67.6 70.4 Nishiyama et al. [104] Japan 2012 Retrospective cohort study ATS/ERS 2000 SGRQ 87 89 66.3 75.0 Noth et al. [105] USA 2012 RCT (ACE-IPF) ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D
SF36145 73 67.0 58.8 Raghu et al. [106] USA 2012 RCT (PANTHER-IPF) ATS/ERS/JRS/ALAT 2011 SGRQ
SF36155 75 68.4 70.7 Shulgina et al. [107] UK 2012 RCT ATS/ERS 2000 SGRQ
EQ5D181 72 71.6 70.7 Swigris et al. [108] USA 2012 RCT (STEP-IPF) ATS/ERS 2005 SGRQ
SF36180 83 69.0 56.8 Lechtzin et al. [109] USA 2013 RCT ATS/ERS/JRS/ALAT 2011 SGRQ
CQLQ20 75 67.6 70.4 Mermigkis et al. [110] Greece 2013 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SF36 23 78 68.2 76.2 Tzouvelekis et al. [111] Greece 2013 Non-randomised Clinical Trial ATS/ERS/JRS/ALAT 2011 SGRQ 14 86 64.4 74.2 Alhamad [112] Saudi Arabia 2014 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SF36 58 57 62.9 65.2 Gaunaurd et al. [71] USA 2014 RCT ATS/ERS/JRS/ALAT 2011 SGRQI 21 68.6 60.5 IPF Clinical Research Network et al. [113] USA 2014 RCT (PANTHER-IPF) ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D
SF36264 78 67.7 72.8 Kozu et al. [114] Japan 2014 Prospective cross-sectional study ATS/ERS/JRS/ALAT 2011 SF36 65 71 67.5 65.3 Lubin et al. [115] USA 2014 Cohort study ATS/ERS 2000 SF36 102 75 70.0 70.0 Morsi et al. [33] Egypt 2014 Cross-sectional study NR NR SGRQ 36 22 53.0 46.3 Richeldi et al. [116] Multi-country 2014 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6 Rifaat et al. [34] Egypt 2014 Prospective observational study ATS/ERS/JRS/ALAT 2011 SGRQ 30 27 54.4 51.9 Vainshelboim et al. [117] Israel 2014 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 32 66 67.3 68.2 Bors et al. [118] USA 2015 Prospective, cross-sectional study ATS/ERS/JRS/ALAT 2011 SF36 46 63 64.6 61.7 Huang et al. [119] China 2015 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 76 93 60.3 77.3 Mermigkis et al. [120] Greece 2015 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SF36 55 NR 70.3 NR Nathan et al. [121] Multi-country 2015 RCT (CAPACITY) ATS/ERS 2000 SGRQ 338 73 66.5 74.7 Raghu et al. [122] Multi-country 2015 RCT ATS/ERS 2000 SGRQ 126 80 65.0 67.2 Vainshelboim et al. [123] Israel 2015 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 28 66 67.3 68.2 Atkins et al. [63] UK 2016 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D
KBILD77 59 76.4 84.3 Bahmer et al. [124] Germany 2016 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
SF1241 75 67.1 75.4 Costabel et al. [125] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6 Ferrara et al. [61] Sweden 2016 Cross-sectional study ATS/ERS/JRS/ALAT 2011 KBILD 71 70 68.3 77.5 Hopkins et al. [47] Canada 2016 Retrospective population-based study ICD NR HUI2 8295 54 NR NR Kolb et al. [126] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1081 78 65.5 78.1 Kotecha et al. [127] UK 2016 Cohort study ATS/ERS/JRS/ALAT 2011 SGRQ 75 58 76.4 83.6 Richeldi et al. [128] Multi-country 2016 RCT (TOMORROW-1, INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1231 79 66.5 79.7 Taniguchi et al. [129] Multi-country 2016 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 322 80 66.0 81.2 Yount et al. [48] USA 2016 Prospective cohort study Patient referred NR ATAQ-IPF
PROMIS220 70 61.0 NR Yu et al. [46] China 2016 RCT CTS NR SGRQ NR NR NR NR Arizono et al. [130] Japan 2017 Prospective observational study ATS/ERS 2002 SGRQ 22 64 70.5 72.2 Azuma et al. [131] Japan 2017 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 126 81 68.3 81.9 Birring et al. [64] Multi-country 2017 RCT ATS/ERS/JRS/ALAT 2011 KBILD
LCQ24 63 67.6 73.0 Cheng et al. [132] Canada 2017 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ 77 69 68.7 73.2 Collard et al. [133] Multi-country 2017 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6 Dowman et al. [52] Australia 2017 RCT NR NR SGRQI 61 67 71.4 75.9 Furukawa et al. [134] Japan 2017 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ 182 85 65.6 79.7 Glaspole et al. [53] Australia 2017 Observational study NR NR SGRQ 422 67 71.3 81.0 Koyama et al. [135] Japan 2017 Prospective cohort study ATS/ERS/JRS/ALAT 2011 Bartel Index 47 89 75.5 75.4 Kreuter et al. [136] Germany 2017 Observational study ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D623 77 69.6 67.5 Lee et al. [137] South Korea 2017 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ 112 84 70.0 85.0 Magnani et al. [35] Italy 2017 Prospective cohort study ATS/ERS/JRS/ALAT 2011 PGWBI 18 45 66.5 62.4 Matsuda et al. [138] Japan 2017 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ 121 82 66.8 81.1 Matsuda et al. [139] Japan 2017 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
COPD106 85 67.1 81.9 Natalini et al. [140] USA 2017 Cross-sectional study ATS/ERS/JRS/ALAT 2011 SF36 50 78 70.8 70.3 Root et al. [141] USA 2017 Observational study ATS/ERS/JRS/ALAT 2011 SF36
LCQ188 56 65.8 73.9 Sokai et al. [142] Japan 2017 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
SF3652 85 72.0 86.1 Swigris et al. [143] Multi-country 2017 RCT (TOMORROW-1) ATS/ERS 2000 SGRQ 426 75 65.1 81.3 Wapenaar et al. [65] Multi-country 2017 Prospective cohort study ATS/ERS 2000 SGRQ
KBILD
EQ5D108 78 70.5 72.5 Atkins et al. [66] UK 2018 Prospective observational study ATS/ERS/JRS/ALAT 2011 KBILD 39 69 75.1 82.7 Bacci et al. [144] USA 2018 Cross-sectional qualitative study and secondary quantitative analysis of clinical trial data ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D30 60 67.7 70.2 Capparelli et al. [70] Argentina 2018 Cohort study- instrument validation ATS/ERS/JRS/ALAT 2011 SGRQI 23 78 71.9 68.9 da Fontoura et al. [40] Brazil 2018 Retrospective cohort study NR SF36 31 60 57.1 49.0 Grufstedt et al. [145] Sweden 2018 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
COPD87 62 70.1 84.21 Kolb et al. [146] Multi-country 2018 RCT (INSTAGE) ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D273 79 70.2 67.0 Mavroudi et al. [147] Greece 2018 Case control study ATS/ERS 2000 SF36 19 58 69.8 75.6 Nishiyama et al. [148] Japan 2018 Prospective observational study ATS/ERS/JRS/ALAT 2011 SGRQ 31 74 72.3 73.8 Nolan et al. [53] UK 2018 Prospective cohort study ATS/ERS/JRS/ALAT 2011 KBILD 65 89 72.0 73.2 Raghu et al. [149] USA 2018 RCT (WRAP-IPF) ATS/ERS/JRS/ALAT 2011 SGRQ 58 82 69.9 75.4 Rajala et al. [150] Finland 2018 Prospective observational study ATS/ERS/JRS/ALAT 2011/2015 RAND36 92 73 75.0 78.0 Rosas et al. [151] USA 2018 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 58 81 67.6 71.1 Swigris et al. [152] Multi-country 2018 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ
EQ5D1081 79 66.8 79.6 Szentes et al. [54] Germany 2018 Prospective observational study NR NR KBILD
EQ5D268 86 63.2 77.4 Takeda et al. [153] Japan 2018 Prospective cohort study ATS/ERS/JRS/ALAT 2015 COPD 25 84 74.4 80.6 Vancheri et al. [154] Multi-country 2018 RCT (INJOURNEY) ATS/ERS/JRS/ALAT 2011 EQ5D 104 86 68.9 84.0 Wuyts et al. [155] Multi-country 2018 Prospective observational study ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D277 77 69.6 80.6 Bosi et al. [156] Italy 2019 Prospective observational study ATS/ERS/JRS/ALAT 2011 SGRQ 47 76 68.7 75.5 Chehere et al. [157] France 2019 Prospective cohort study ATS/ERS 2001 SF36 19 75 65.0 75.0 Eken et al. [158] Turkey 2019 Cross-sectional study ATS/ERS/JRS/ALAT 2011 SGRQ 40 78 65.5 86.6 Justice et al. [159] USA 2019 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 14 88 70.8 NR Kalafatis et al. [69] Sweden 2019 Observational study ATS/ERS/JRS/ALAT 2011 KBILD 348 72 72.0 70.2 Kimman et al. [57] Netherlands 2019 Prospective cohort study NR NR PESaM
EQ5D188 76 69 NR Kreuter et al. [55] Germany 2019 Observational study NR NR SGRQ
EQ5D424 77 68.7 36.1 Nolan et al. [56] UK 2019 Prospective cohort study NR NR KBILD 209 61 70.0 71.9 Pan et al. [44] China 2019 Cross-sectional study ATS/ERS/JRS/ALAT 2011 SGRQ
ATAQ-IPF20 70 58.3 NR Prior et al. [73] Denmark 2019 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQI
SGRQ
KBILD150 81 72.9 87.2 Ryerson et al. [160] Multi-country 2019 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1060 79 66.8 79.6 Sinha et al. [36] UK 2019 Prospective cohort study NR NR KBILD 57 33 62.0 80.0 Wallaert et al. [161] France 2019 Prospective cohort study ATS/ERS/JRS/ALAT 2011 VSRQ 61 75 66.8 68.6 Witt et al. [162] Multi-country 2019 Prospective observational study ATS/ERS/JRS/ALAT 2011 SF36 258 73 67.3 62.7 Xu et al. [163] China 2019 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 101 54 64.3 80.8 Yuen et al. [164] USA 2019 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 20 65 69.8 66.0 Bloem et al. [37] Netherlands 2020 Cross-sectional study ATS/ERS/JRS/ALAT 2011 EQ5D
QoL-RIQ59 45 73.0 83.2 Case et al. [165] USA 2020 Retrospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D
SF12662 75 70.0 69.9 Janssen et al. [166] USA 2020 RCT ATS/ERS/JRS/ALAT 2011 SGRQ 22 71 90.9 73.4 Kreuter et al. [167] Multi-country 2020 RCT (INPULSIS-1, INPULSIS-2) ATS/ERS 2000 SGRQ 1061 79 66.8 79.6 Moor et al. [67] Netherlands 2020 RCT ATS/ERS/JRS/ALAT 2018 PESaM
EQ5D
KBILD90 91 71.0 80.1 O'Brien et al. [168] USA 2020 Cross-sectional study ATS/ERS/JRS/ALAT 2011 SGRQ
EQ5D
SF12859 74 70.0 69.7 Prior et al. [72] Denmark 2020 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQI
SGRQ
KBILD150 81 72.9 87.2 Richeldi et al. [169] Multi-country 2020 RCT (INPULSIS-1, INPULSIS-2, INSTAGE) ATS/ERS
ATS/ERS/JRS/ALAT2000
2011SGRQ 1197 79 67.1 78.0 Tzouvelekis et al. [68] Greece 2020 Prospective cohort study ATS/ERS/JRS/ALAT 2011 SGRQ
KBILD98 83 70.8 77.0 All means are calculated pooled means. ACE-IPF: Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis; ATS/ERS: American Thoracic Society/European Respiratory Society; ATS/ERS/JRS/ALAT: American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society; ATAQ-IPF: A Tool to Assess Quality of life in IPF; BUILD: Bosentan Use in Interstitial Lung Disease; CQLQ: The Cough Quality of Life Questionnaire; CTS: Chinese Thoracic Society; EQ5D: EuroQol; FVC: Forced vital capacity; HUI2: Health Utilities Index Mark 2; IPF: idiopathic pulmonary fibrosis; K-BILD: King's Brief Interstitial Lung Disease; LCQ: Leicester Cough Questionnaire; NR: not reported; PANTHER Prednisone, Azathioprine, and N-acetylcysteine in Participants With IPF; PESaM: Patient Experiences and Satisfaction with Medications Questionnaire; PGWBI: The Psychological General Well-Being Index; PROMIS: Participant Reported Outcomes Measurement Information System; QoL-RIQ: Quality-of-Life for Respiratory Illness; RAND36: Research and Development 36 item health survey; RCT: Randomised controlled trial; SF12: Short Form-12; SF36 Short Form-36; SGRQ: St George's Questionnaire; SGRQI: IPF-specific version of the SGRQ; STEP-IPF: Sildenafil Trial Of Exercise Performance In Idiopathic Pulmonary Fibrosis; VSRQ: Visual Simplified Respiratory Questionnaire; WHOQoL: WHO Quality of Life Questionnaire; WRAP-IPF: Treatment of IPF With Laparoscopic Anti-Reflux Surgery.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary_material ERR-0154-2020_Supplementary_material
Vol 29 Issue 158
Table of Contents
Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
